Disclosed is a system including a flow control assembly. The system may include a flow regulating shunt system, for various purposes. The flow control assembly may be controlled according to selected parameters and methods.

In one aspect, an implantable shunt system is disclosed that, in one example implementation, includes a resilient member and a connected fluid regulating device. The fluid regulating device selectively permits fluid flow through an opening valve of an implantable shunt according to an adjustable opening pressure. The opening pressure is proportional to an amount of tension on the resilient member. One or more tension sensors that are connected to the resilient member measure an amount of tension on the resilient member. The tension sensors generate tension data that corresponds to the measured amount of tension. The system further includes a communication unit with a transmitting unit that transmits the measured data over a communication link. The system also includes a reading unit that receives the transmitted tension data over the communication link. The reading unit includes a connector that electrically connects the reading unit to the transmission unit.

This disclosure describes devices and methods used to inject or aspirate fluid into or from various regions of the human body, such as the anterior chamber of the eye. The disclosed devices and methods provide improvements over conventional devices and methods in that an operator can perform a procedure using the disclosed device without an assistant. The disclosed devices and methods allow one-handed injection or aspiration of fluid into or from body tissue, and provide means for controlling the volume of injected or aspirated fluid.

The present invention provides methods and systems for conditioning cerebrospinal fluid (CSF) by removing target compounds from CSF. The systems provide for a catheter flow path and exchange of a majority volume portion of CSF in the CSF space. The removal and/or delivery of specific compounds can be tailored to the pathology of the specific disease. The removal is targeted and specific, for example, through the use of specific size-exclusion thresholds, antibodies against specific toxins, and other chromatographic techniques, as well as delivery and/or removal of targeted therapeutic agents.

An implantable intracranial pulse pressure modulator for treating hydrocephalus in patients of all ages is disclosed as well as a system and method for use of the same. In one embodiment of the implantable intracranial pulse pressure modulator, two one-way valves are interposed in parallel, opposing orientations between a vestibule and a chamber. One of the one-way valves, in response to systole, provides fluid communication from the vestibule to the chamber such that a small aliquot of cerebrospinal fluid (CSF) is displaced from a cerebral ventricle into a ventricular catheter, thereby reducing intraventricular systolic pressure. The other one-way valve, in response to diastole, provides fluid communication from the chamber to the vestibule such that the same volume of CSF is reintroduced into a cerebral ventricle, thereby increasing intraventricular diastolic pressure. Together, both processes work synergistically to reduce intraventricular pulse pressure in order to treat hydrocephalus.

Filtering device for filtering cerebrospinal fluid are disclosed. An example filtering device may include a filter housing having an inlet for receiving cerebrospinal fluid from a patient and an outlet for returning filtered cerebrospinal fluid to the patient. The filter housing may include a plurality of layers coupled together and defining a fluid pathway therein between the inlet and the outlet. A filtering section may be defined within the filter housing along the fluid pathway. The filtering section may include a widened region of the fluid pathway that is configured to slow the passage of fluid therethrough.

Cerebrospinal fluid (CSF) and other fluid amelioration systems completely or partially implantable within a mammalian subject and associated methods include a substrate and an agent for amelioration of a toxic biomolecule present in the CSF or fluid, wherein the agent is disposed on or within the substrate.

Systems, catheters, and methods for accessing and treating along the central nervous system are disclosed. A system for processing cerebrospinal fluid is disclosed. The system may include a catheter having a proximal subassembly and a distal subassembly. A pump and filtration system may be coupled to the catheter. An infusion lumen for infusing cerebrospinal fluid filtered by the pump and filtration system may be defined along the distal subassembly. The distal subassembly may define a plurality of infusion openings in fluid communication with the infusion lumen. The infusion openings may increase in size distally along the distal subassembly.

An embodiment provides a method for treating a body fluid of a patient with Covid-19, including: removing the body fluid from a patient, wherein the body fluid comprises a Covid-19 targeted pathogenic antigen (TPA); applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with the Covid-19 targeted pathogenic antigen in the body fluid to form an antibody-TPA complex, wherein the antibody comprises a radiofrequency absorption enhancer forming an antibody-radio frequency enhancing moiety-virion complex (ARFVC); removing the ARFVC from the body fluid using a radiofrequency source; and returning the body fluid to the patient. Other aspects are described and claimed.

A valve assembly for controlled drainage or delivery of a fluid from or to a patient including a first port (182), a second port (184), a diaphragm chamber and a diaphragm (132) dividing the diaphragm chamber into a first chamber cavity (158A) and a second chamber cavity (158B). The diaphragm being deflectable toward a first wall of the diaphragm chamber wherein the first chamber cavity contracts and the second chamber cavity expands, and oppositely toward a second wall of the diaphragm chamber wherein the second chamber cavity contracts and the first chamber cavity expands. A valve (212) is actuatable between a first actuation state that establishes fluid communication between the first port and the second chamber cavity and separately between the second port and the first chamber cavity. The valve also having a second actuation state that establishes fluid communication between the first port and the first chamber cavity, and separately between the second port and the second chamber cavity.